Suchergebnisse

Abstract
Mindfulness originated from Buddhist contemplative practice 2500 years ago. Mindfulness has increasingly been integrated into a variety of health care programs to address issues such as chronic pain, mental health problems, and addictions. The purpose of this study was to evaluate the feasibility of teaching problem gamblers about mindfulness meditation as part of regular treatment for problem gambling. The study evaluated an 8-week mindfulness group program that included 17 clients from the Problem Gambling Institute of Ontario at the Centre for Addiction and Mental Health (88% male) using questionnaires that were distributed before the first group session and after the final group session. The evaluation was a mixed method design that included both qualitative and quantitative feedback about the group. All of the participants showed an improvement in their levels of mindfulness after the 8-week treatment program. The Mindfulness Attention Awareness Scale (MAAS) scores increased from a pre-test score of 3.65 (SD = 1.01) to a post-test score of 4.40 (SD = 0.78). Qualitative feedback about the group also highlighted a number of improvements in the clients' lives that included being more in control, relaxed and able to stay in the now. The results indicated that mindfulness was successfully taught during the 8-week group program. This study evaluated the suitability of mindfulness as an intervention as part of a problem gambling treatment service. However, the study did not evaluate whether mindfulness improved the clients' ability to resist relapse. Future studies are needed to examine the long-term impact of mindfulness sessions.

A hallmark of cancer cells is their ability to reprogram nutrient metabolism. Thus, disruption to this phenotype is a potential avenue for anti-cancer therapy. Herein we used a phenotypic chemical library screening approach to identify molecules that disrupted nutrient metabolism (by increasing cellular oxygen consumption rate) and were toxic to cancer cells. From this screen we discovered a 1,4-Naphthoquinone (referred to as BH10) that is toxic to a broad range of cancer cell types. BH10 has improved cancer-selective toxicity compared to doxorubicin, 17-AAG, vitamin K3, and other known anti-cancer quinones. BH10 increases glucose oxidation via both mitochondrial and pentose phosphate pathways, decreases glycolysis, lowers GSH:GSSG and NAPDH/NAPD(+) ratios exclusively in cancer cells, and induces necrosis. BH10 targets mitochondrial redox defence as evidenced by increased mitochondrial peroxiredoxin 3 oxidation and decreased mitochondrial aconitase activity, without changes in markers of cytosolic or nuclear damage. Over-expression of mitochondria-targeted catalase protects cells from BH10-mediated toxicity, while the thioredoxin reductase inhibitor auranofin synergistically enhances BH10-induced peroxiredoxin 3 oxidation and cytotoxicity. Overall, BH10 represents a 1,4-Naphthoquinone with an improved cancer-selective cytotoxicity profile via its mitochondrial specificity. ; Hope Funds for Cancer Research [HFCR-14-06-04]; Cancer Institute NSW ECF [2018/ECF003]; UNSW; Cancer Institute NSW CDF; Australian Postgraduate AwardAustralian Government; UNSW Sydney ; FLB was supported by a postdoctoral fellowship from the Hope Funds for Cancer Research (HFCR-14-06-04) and is currently supported by a Cancer Institute NSW ECF (2018/ECF003). Financial support was provided in part by a UNSW faculty collaboration grant to KLH and NK. JM is supported by a Cancer Institute NSW CDF. GEM was supported by an Australian Postgraduate Award. KGRQ is supported by a UNSW Sydney Scientia Fellowship.